問卷

TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Hematology & Oncology

Division of General Surgery

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

趙祖怡Chao, Tsu-Yi
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

篩選

List

106Cases

2014-09-01 - 2018-11-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2019-04-01 - 2027-04-24

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2006-10-18 - 2008-06-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-04-01 - 2018-12-31

Phase I

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
  • Condition/Disease

    Breast Cancer

  • Test Drug

    Oraxol

Participate Sites
6Sites

Terminated6Sites

趙大中
Taipei Veterans General Hospital

Division of Radiation Therapy

2017-09-01 - 2021-12-31

Phase I

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007
  • Condition/Disease

    Breast Cancer

  • Test Drug

    Oraxol

Participate Sites
7Sites

Terminated6Sites

2017-04-27 - 2018-12-31

Phase I

A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers
  • Condition/Disease

    Gastric Cancer/Esophageal Cancer/Gastro-esophageal Cancer

  • Test Drug

    Oraxol + Ramucirumab

Participate Sites
7Sites

Terminated6Sites

2018-09-01 - 2019-02-28

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2018-10-16 - 2019-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-12-20 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites